Homepage500124 • BOM
add
Dr Reddy's Laboratories Ltd
Vorige slotkoers
₹ 1.219,65
Dag-range
₹ 1.216,20 - ₹ 1.233,15
Jaar-range
₹ 1.120,01 - ₹ 1.420,20
Beurswaarde
1,02Â bln. INR
Gem. volume
86,11K
Koers/winst
19,06
Dividendrendement
0,65%
Primaire beurs
NSE
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(INR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 83,59Â mld. | 15,85% |
Bedrijfskosten | 30,34Â mld. | 19,95% |
Netto inkomsten | 14,13Â mld. | 2,49% |
Netto winstmarge | 16,91 | -11,51% |
Winst per aandeel | 16,94 | 1,81% |
EBITDA | 23,43Â mld. | 13,31% |
Effectief belastingtarief | 25,10% | — |
Balans
Totale activa
Totale passiva
(INR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 59,92Â mld. | -17,41% |
Totale activa | 481,06Â mld. | 29,02% |
Totale passiva | 159,49Â mld. | 51,91% |
Totaal aandelenvermogen | 321,56 mld. | — |
Uitstaande aandelen | 833,12 mln. | — |
Koers-boekwaardeverhouding | 3,20 | — |
Rendement op activa | 9,88% | — |
Rendement op kapitaal | 12,81% | — |
Kasstroom
Nettomutatie in liquide middelen
(INR) | dec 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 14,13Â mld. | 2,49% |
Operationele kasstroom | 6,62Â mld. | 39,75% |
Kasstroom uit beleggingen | -5,46Â mld. | 66,27% |
Kasstroom uit financiering | 590,00Â mln. | -88,83% |
Nettomutatie in liquide middelen | 1,75Â mld. | 129,12% |
Vrije kasstroom | -382,75Â mln. | 90,46% |
Over
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Opgericht
1984
Hoofdvestiging
Website
Werknemers
27.048